Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 29

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 29
---
 Ended June 30, 2025 

			Change 

			June 30, 2025

			June 30, 2024

			$ 

			Program-specific external costs:

			EB06

			$
			292,200

			$
			-

			$
			292,200

			EB05

			1,269,963

			1,769,712

			(499,749
			)

			Other development and discovery programs

			101,227

			193,696

			(92,469
			)

			Total program-specific costs

			1,663,390

			1,963,408

			(300,018
			)

			Unallocated internal costs

			Non-program specific external costs

			1,199

			9,663

			(8,464
			)

			Unallocated internal costs

			778,602

			805,029

			(26,427
			)

			Total unallocated internal costs

			779,801

			814,692

			(34,891
			) 

			Total research and development costs

			2,443,191

			2,778,100

			(334,909
			)

			●

			R&D expenses decreased by $0.4 million to $2.4 million for the nine months ended June 30, 2025 compared to $2.8 million for the same period last year primarily due to a decrease in external research expenses related to EB05 (paridiprubart), which was partially offset by an increase in costs related to EB06 associated with preparations for the Phase 2 clinical study. Our R&D expenses consist primarily of employee-related expenses, including salaries, benefits, taxes, travel, and share-based compensation expense for personnel in R&D functions; expenses related to process development and production of product candidates paid to contract manufacturing organizations, including the cost of acquiring, developing, and manufacturing research material; costs associated with clinical activities, including expenses for contract research organizations; and clinical trials and activities related to regulatory filings for our product candidates, including regulatory consultants.

			●

			G&A expenses decreased by $0.2 million to $3.0 million for the